NEW YORK, NY / ACCESSWIRE / August 15, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Kanzhun Limited (NASDAQ:BZ)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/kanzhun-limited-loss-submission-form?prid=18550&wire=1
Lead Plaintiff Deadline: September 10, 2021
Class Period: June 11, 2021 - July 2, 2021
Allegations against BZ include that: (1) Kanzhun would face an imminent cybersecurity review by the Cyberspace Administration of China ("CAC"); (2) the CAC would require Kanzhun to suspend new user registration on its BOSS Zhipin app; (3) Kanzhun needed to "to conduct a comprehensive examination of cybersecurity risks"; (4) Kanzhun needed to "enhance its cybersecurity awareness and technology capabilities"; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
CarLotz, Inc. (NASDAQ:LOTZ)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/carlotz-inc-loss-submission-form?prid=18550&wire=1
Lead Plaintiff Deadline: September 7, 2021
Class Period: December 30, 2020 - May 25, 2021
Allegations against LOTZ include that: (1) due to a surge in inventory during the second half of fiscal 2020, CarLotz was experiencing a "logjam" resulting in slower processing and higher days to sell; (2) as a result, the Company's gross profit per unit would be negatively impacted; (3) to minimize returns to the corporate vehicle sourcing partner responsible for more than 60% of CarLotz's inventory, the Company was offering aggressive pricing; (4) as a result, CarLotz's gross profit per unit forecast was likely inflated; (5) this Company's corporate vehicle sourcing partner would likely pause consignments to the Company due to market conditions, including increasing wholesale prices; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Ardelyx, Inc. (NASDAQ:ARDX)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/ardelyx-inc-loss-submission-form?prid=18550&wire=1
Lead Plaintiff Deadline: September 28, 2021
Class Period: August 6, 2020 - July 19, 2021
Allegations against ARDX include that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong